1. Home
  2. ANL vs MPT Comparison

ANL vs MPT Comparison

Compare ANL & MPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

SELL

Current Price

$10.00

Market Cap

998.8M

Sector

N/A

ML Signal

SELL

Logo Medical Properties Trust Inc. common stock

MPT

Medical Properties Trust Inc. common stock

HOLD

Current Price

$1.50

Market Cap

983.5M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
MPT
Founded
2004
2003
Country
Singapore
United States
Employees
N/A
121
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
983.5M
IPO Year
2022
2004

Fundamental Metrics

Financial Performance
Metric
ANL
MPT
Price
$10.00
$1.50
Analyst Decision
Strong Buy
Hold
Analyst Count
7
7
Target Price
★ $29.50
$3.55
AVG Volume (30 Days)
229.1K
★ 21.8M
Earning Date
08-14-2026
10-29-2026
Dividend Yield
N/A
★ 21.56%
EPS Growth
N/A
★ 88.56
EPS
N/A
★ 0.05
Revenue
N/A
★ $972,022,000.00
Revenue This Year
$243.83
N/A
Revenue Next Year
N/A
$4.41
P/E Ratio
★ N/A
$33.50
Revenue Growth
★ N/A
N/A
52 Week Low
$0.88
$1.62
52 Week High
$17.25
$6.47

Technical Indicators

Market Signals
Indicator
ANL
MPT
Relative Strength Index (RSI) 41.78 11.38
Support Level $8.95 N/A
Resistance Level $11.75 $5.32
Average True Range (ATR) 1.03 0.19
MACD 0.20 -0.03
Stochastic Oscillator 42.35 1.40

Price Performance

Historical Comparison
ANL
MPT

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About MPT Medical Properties Trust Inc. common stock

Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.

Share on Social Networks: